Celldex touted a double phase 3 trial win in patients with treatment-refractory chronic spontaneous urticaria.
- Home |
- Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
- September 22, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
